UK will dominate next-generation mRNA drug delivery worldwide

The H-Investments Team

Oct 6, 2023 — 1 min read

London, UK, 4 October 2023 - A new report by the BioIndustry Association (BIA) reveals how the UK is poised to become a global leader in mRNA medicine, an emerging technology that rose to prominence during the COVID pandemic but has vast potential beyond. The importance of this technology has been highlighted by the recent Nobel Prize in Physiology or Medicine award to Dr. Kariko and Dr. Weissman for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.

Steve Bates, CEO of the BIA, said: "mRNA Revolution: A New Generation of Medicine explains how the UK will lead the way in developing and delivering next-generation mRNA medicines for a wide range of diseases, beyond just COVID-19. This new report explains not only the technology and its potential but lifts the lid on why the UK has the capability, people, and vision to lead the world in delivering the next generation of medicines”.

Source: BioIndustry

Next-Generation RNA company Inverna Therapeutics is launched

The newly formed company will use splicing technology to develop safer and more effective RNA medicines for severe genetic illnesses On January 7, 2025, Argobio shared the exciting news about the launch of Inverna Therapeutics, a new biotech company based in Denmark that focuses on innovative RNA therapeutics, co-founded with

The Japanese MHLW Approves Takeda's HYQVIA Subcutaneous Injection

HYQVIA is the first and only facilitated subcutaneous immunoglobulin licensed in Japan to treat Agammaglobulinemia or Hypogammaglobulinemia On December 27, 2024, Takeda shared that the Japanese Ministry of Health, Labour and Welfare (MHLW) has given the green light to HYQVIA [ Human Immune Globulin Infusion 10% Human with Recombinant Human Hyaluronidase]

Roche reports the Prasinezumab aids in early-stage Parkinson's

The main goal of the Phase IIb study wasn't met with statistically significant results, but there is still some good news On Dec. 18, 2024, Roche shared results from a Phase IIb study (PADOVA) where prasinezumab, an investigational monoclonal antibody (mAb), did not meet the study’s primary

Novo Nordisk is Funding New Manufacturing Facility in Denmark

Novo Nordisk will establish a modular, adaptable production facility in Odense, Denmark Novo Nordisk announced a $1.2 billion production plant in Odense, Denmark, on Dec. 16, 2024. The facility will house present and future hemophilia treatment products. In a press release, Novo Nordisk said this investment is its first

Read more

Next-Generation RNA company Inverna Therapeutics is launched

The Japanese MHLW Approves Takeda's HYQVIA Subcutaneous Injection

Roche reports the Prasinezumab aids in early-stage Parkinson's

Novo Nordisk is Funding New Manufacturing Facility in Denmark